Profile data is unavailable for this security.
About the company
TIBET RHODIOLA PHARMACEUTICAL HOLDING CO. is a China-based company principally engaged in the production and distribution of pharmaceuticals. The Company operates its businesses through the distribution of proprietary drug products, as well as the processing of pharmaceuticals and others. The Company conducts its businesses primarily in South China, North China, East China, Central China and overseas markets.
- Revenue in CNY (TTM)2.93bn
- Net income in CNY828.15m
- Incorporated1999
- Employees601.00
- LocationTibet Rhodiola Pharmaceutical Holding CoNo. 19, Beijing Middle RoadLASA 850000ChinaCHN
- Phone+86 2 886653915
- Fax+86 2 886660740
- Websitehttp://www.xzyy.cn
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mayinglong Pharmaceutical Group Co Ltd | 3.42bn | 473.79m | 9.44bn | 2.88k | 19.92 | 2.45 | -- | 2.76 | 1.10 | 1.10 | 7.94 | 8.94 | 0.6648 | 6.05 | 10.01 | 1,188,102.00 | 9.35 | 10.82 | 11.58 | 13.47 | 43.86 | 41.18 | 14.07 | 14.08 | 4.06 | -- | 0.0946 | 33.04 | -11.20 | 7.38 | -7.46 | 20.26 | 58.33 | 21.67 |
Liaoning Chengda Biotechnology Co Ltd | 1.76bn | 352.53m | 9.44bn | 1.73k | 26.87 | 0.9885 | -- | 5.37 | 0.8438 | 0.8438 | 4.23 | 22.93 | 0.1766 | 0.7386 | 1.48 | 1,015,870.00 | 3.54 | 10.63 | 3.66 | 11.01 | 81.24 | 85.74 | 20.04 | 39.56 | 17.34 | -- | 0.0019 | 31.53 | -3.58 | 4.71 | -34.75 | -5.56 | 39.78 | -- |
Heilongjiang ZBD Pharmaceutical Co Ltd | 2.22bn | 522.07m | 9.58bn | 2.55k | 18.30 | 1.21 | -- | 4.32 | 0.5556 | 0.5556 | 2.36 | 8.43 | 0.1757 | 0.6759 | 0.6464 | 870,758.90 | 4.10 | 3.48 | 5.54 | 4.78 | 64.84 | 38.93 | 23.37 | 10.08 | 2.18 | -- | 0.2951 | 27.18 | -25.50 | 2.45 | 155.00 | 0.4417 | -25.68 | 4.05 |
Guobang Pharma Ltd | 5.43bn | 659.59m | 10.23bn | 4.23k | 15.50 | 1.34 | -- | 1.88 | 1.18 | 1.18 | 9.72 | 13.70 | 0.5504 | 3.05 | 7.19 | 1,283,877.00 | 6.66 | 10.36 | 8.54 | 14.24 | 23.75 | 27.49 | 12.10 | 15.01 | 1.67 | -- | 0.1799 | 18.24 | -6.49 | 10.28 | -33.49 | 23.77 | 35.60 | -- |
Tibet Rhodiola Pharmaceutical Holding Co | 2.93bn | 828.15m | 10.37bn | 601.00 | 11.25 | 2.74 | -- | 3.54 | 2.86 | 2.86 | 9.64 | 11.76 | 0.5751 | 1.65 | 4.55 | 4,873,193.00 | 16.43 | 12.44 | 22.82 | 15.71 | 93.55 | 90.51 | 28.56 | 20.43 | 2.71 | 8.45 | 0.1636 | 50.41 | 22.69 | 24.98 | 116.56 | 30.01 | -1.48 | 48.97 |
Zhejiang CONBA Pharmaceutical Co., Ltd. | 6.42bn | 457.64m | 10.41bn | 8.41k | 22.75 | 1.53 | -- | 1.62 | 0.1781 | 0.1781 | 2.50 | 2.66 | 0.5903 | 2.44 | 4.39 | 762,894.60 | 4.66 | 6.77 | 6.76 | 10.50 | 52.88 | 63.24 | 7.90 | 11.10 | 1.30 | 26.89 | 0.109 | 42.32 | 12.20 | -0.8267 | 65.20 | -6.21 | -11.64 | 5.92 |
BrightGene Bio-Medical Technology Co Ltd | 1.25bn | 199.39m | 10.49bn | 1.16k | 53.48 | 4.39 | -- | 8.40 | 0.4645 | 0.4645 | 2.95 | 5.66 | 0.2488 | 1.71 | 4.04 | 1,082,012.00 | 3.13 | 6.53 | 3.87 | 7.93 | 54.94 | 56.93 | 12.58 | 19.90 | 1.39 | 4.78 | 0.4994 | 29.31 | 15.94 | 23.68 | -15.51 | 22.56 | 29.13 | -- |
Henan Lingrui Pharmaceutical Co., Ltd. | 3.52bn | 664.16m | 10.88bn | 2.53k | 16.35 | 4.00 | -- | 3.09 | 1.17 | 1.17 | 6.22 | 4.80 | 0.7764 | 2.17 | 12.17 | 1,390,046.00 | 14.66 | 10.68 | 24.66 | 16.56 | 72.45 | 74.42 | 18.89 | 14.92 | 0.8563 | -- | 0.037 | 72.80 | 10.31 | 10.03 | 22.09 | 18.49 | -16.47 | 39.77 |
Data as of Sep 20 2024. Currency figures normalised to Tibet Rhodiola Pharmaceutical Holding Co's reporting currency: Chinese Yuan Renminbi CNY
Holder | Shares | % Held |
---|---|---|
HuaAn Fund Management Co., Ltd.as of 31 Dec 2023 | 1.93m | 0.60% |
China Asset Management Co., Ltd.as of 31 Dec 2023 | 1.64m | 0.51% |
Everbright PGIM Fund Management Co. Ltd.as of 31 Dec 2023 | 1.58m | 0.49% |
Rongtong Fund Management Co., Ltd.as of 31 Dec 2023 | 1.04m | 0.32% |
The Vanguard Group, Inc.as of 04 Sep 2024 | 945.63k | 0.29% |
Zhong Ou Asset Management Co., Ltdas of 31 Dec 2023 | 910.10k | 0.28% |
Baoying Fund Management Co., Ltd.as of 31 Dec 2023 | 793.13k | 0.25% |
Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 748.02k | 0.23% |
China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 608.53k | 0.19% |
Essence Fund Co., Ltd.as of 31 Dec 2023 | 598.13k | 0.19% |
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.